(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Oldest evidence of human fire-making discovered at site in England- A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- A hospital discharged a woman in labor. This lawmaker wants change.
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language
- Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut
- I'm an 83-year-old yoga instructor. I'm not your typical grandma — I still work to feel fulfilled and supplement my Social Security.
- 7 Popular Vacation destinations In China
